BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
February 07, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with...
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
February 06, 2024 08:30 ET
|
BriaCell Therapeutics Corp.
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
January 30, 2024 22:48 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
January 04, 2024 08:45 ET
|
BriaCell Therapeutics Corp.
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cyclesPowerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular...
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
December 28, 2023 08:55 ET
|
BriaCell Therapeutics Corp.
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune...
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
December 20, 2023 08:40 ET
|
BriaCell Therapeutics Corp.
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies*Progression Free Survival (PFS) was...
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
December 06, 2023 09:31 ET
|
BriaCell Therapeutics Corp.
Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*).32 out of 42 patients treated...
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
December 06, 2023 09:00 ET
|
BriaCell Therapeutics Corp.
BriaCell’s Bria-IMT™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning “Cold” tumors “Hot” on ImmunoPET imagingAdvanced protein array technologies...
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
November 30, 2023 07:00 ET
|
BriaCell Therapeutics Corp.
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction...
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND
November 03, 2023 08:31 ET
|
BriaCell Therapeutics Corp.
BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies Data supports further development of...